

Greater China – Week in Review

Highlights: RMB remains resilient despite renewed tariff threat

Tariffs returned to the spotlight last week after President Trump's Section 122 flat 10% global tariff expired upon reaching its 150-day statutory limit. It was replaced on the same day by new Section 301 tariffs linked to forced-labour concerns, set at either 10% or 12.5% across 60 economies covering 99% of US imports. China was placed in the higher 12.5% tier.

At first glance, the new tariff represents a 2.5 percentage-point increase for China. However, its coverage is considerably narrower than the previous Section 122 measure, as it exempts all goods already subject to Section 232 tariffs, as well as energy, critical minerals, gold and a large share of agricultural products. As a result, the increase in the effective tariff rate on Chinese imports should be meaningfully smaller than the headline 2.5 percentage points.

We therefore believe the direct incremental drag on China's economy and exports will be limited. First, the net increase in the effective tariff rate is relatively small and remains well below previous peaks. Second, the Busan trade truce remains intact. The latest tariff measure is broad-based and does not specifically target China, reducing the risk of an immediate escalation in bilateral tensions.

Nevertheless, the latest development is a timely reminder that tariffs remain an important tail risk for markets. On 11 and 12 March, the Trump administration launched two separate Section 301 investigations covering 16 and 60 economies, respectively, citing excess-capacity and forced-labour concerns. While the findings of the forced-labour investigation have now been released, the outcome of the excess-capacity investigation remains pending.

The Office of the US Trade Representative is currently conducting three Section 301 investigations: an excess-capacity investigation involving 16 economies, including China, the European Union and Singapore; an investigation into intellectual property protection in Vietnam; and an investigation into innovative pharmaceuticals in Germany. Each could potentially result in additional Section 301 tariffs.

Our base case is that the US administration may delay announcing the findings of the excess-capacity investigation ahead of the Trump-Xi summit scheduled for 24 September, to avoid undermining the diplomatic backdrop. Therefore, the next major catalysts for China's effective tariff rate will be the outcome of the second Section 301 investigation on excess capacity and the September meeting between Presidents Xi and Trump.

Despite the latest round of tariffs, the RMB remained resilient, with onshore USD/CNY hovering around 6.77 level.

We also hosted our flagship economic forum last week, bringing together

Tommy Xie Dongming
Head of Asia Macro Research

Keung Ching (Cindy)
Hong Kong & Macau Economist

prominent speakers from the US, China and Europe. One of our guest speakers from China expected USD/CNY to trend towards 6.30 over the next 12 months, supported by China's resilient economic fundamentals, strong manufacturing capabilities and sustained external competitiveness.

This constructive view was echoed by another Chinese speaker—a former central bank official—at one of our subsidiary events two weeks ago. He similarly expressed optimism about the RMB's medium-term outlook. While 6.30 represents a relatively bullish forecast, the consistency of these views suggests that confidence in the RMB may be gradually improving, particularly against the backdrop of China's sizeable trade surplus and resilient export performance.

For this week, key focus will shift to the July Politburo meeting. With retail sales growth still substantially below the implied medium-term target, we expect policymakers to announce additional consumption-support measures at the July Politburo meeting, particularly to stimulate durable goods consumption. At the same time, policymakers are placing increasing emphasis on services consumption, which is not fully captured by traditional retail sales data.

Key Events	
Facts	OCBC Opinions
President Trump's Section 122 flat 10% global tariff expired upon reaching its 150-day statutory limit. It was replaced on the same day by new Section 301 tariffs linked to forced-labour concerns, set at either 10% or 12.5% across 60 economies covering 99% of US imports. China was placed in the higher 12.5% tier.	- At first glance, the new tariff represents a 2.5 percentage-point increase for China. However, its coverage is considerably narrower than the previous Section 122 measure, as it exempts all goods already subject to Section 232 tariffs, as well as energy, critical minerals, gold and a large share of agricultural products. As a result, the increase in the effective tariff rate on Chinese imports should be meaningfully smaller than the headline 2.5 percentage points. - We therefore believe the direct incremental drag on China's economy and exports will be limited. First, the net increase in the effective tariff rate is relatively small and remains well below previous peaks. Second, the Busan trade truce remains intact. The latest tariff measure is broad-based and does not specifically target China, reducing the risk of an immediate escalation in bilateral tensions. - Nevertheless, the latest development is a timely reminder that tariffs remain an important tail risk for markets. On 11 and 12 March, the Trump administration launched two separate Section 301 investigations covering 16 and 60 economies, respectively, citing excess-capacity and forced-labour concerns. While the findings of the forced-labour investigation have now been released, the outcome of the excess-capacity investigation remains pending. - The Office of the US Trade Representative is currently conducting three Section 301 investigations: an excess-capacity investigation involving 16 economies, including China, the European Union and Singapore; an investigation into intellectual property protection in Vietnam; and an investigation into innovative pharmaceuticals in Germany. Each could potentially result in additional Section 301 tariffs. - Our base case is that the US administration may delay announcing the findings of the excess-capacity investigation ahead of the Trump-Xi summit scheduled for 24 September, to avoid undermining the diplomatic backdrop. Therefore, the next major catalysts for China's effective tariff rate will be the outcome of the second Section 301 investigation on excess capacity and the September meeting between Presidents Xi and Trump.

Disclaimers

This report is solely for information purposes and general circulation only and may not be published, circulated, reproduced or distributed in whole or in part to any other person without our prior written consent. This report should not be construed as an offer or solicitation for the subscription, purchase or sale of the securities/instruments mentioned herein or to participate in any particular trading or investment strategy. Any forecast on the economy, stock market, bond market and economic trends of the markets provided is not necessarily indicative of the future or likely performance of the securities/instruments. Whilst the information contained herein has been compiled from sources believed to be reliable and we have taken all reasonable care to ensure that the information contained in this report is not untrue or misleading at the time of publication, we cannot guarantee and we make no representation as to its accuracy or completeness, and you should not act on it without first independently verifying its contents. The securities/instruments mentioned in this report may not be suitable for investment by all investors. Any opinion or estimate contained in this report is subject to change without notice. We have not given any consideration to and we have not made any investigation of the investment objectives, financial situation or particular needs of the recipient or any class of persons, and accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of the recipient or any class of persons acting on such information or opinion or estimate. This report may cover a wide range of topics and is not intended to be a comprehensive study or to provide any recommendation or advice on personal investing or financial planning. Accordingly, it should not be relied on or treated as a substitute for specific advice concerning individual situations. Please seek advice from a financial adviser regarding the suitability of any investment product taking into account your specific investment objectives, financial situation or particular needs before you make a commitment to purchase the investment product. In the event that you choose not to seek advice from a financial adviser, you should consider whether the investment product mentioned herein is suitable for you. Oversea-Chinese Banking Corporation Limited ("OCBC Bank"), Bank of Singapore Limited ("BOS"), OCBC Securities Private Limited ("OSPL") and their respective related companies, their respective directors and/or employees (collectively "Related Persons") may or might have in the future, interests in the investment products or the issuers mentioned herein. Such interests include effecting transactions in such investment products, and providing broking, investment banking and other financial or securities related services to such issuers as well as other parties generally. OCBC Bank and its Related Persons may also be related to, and receive fees from, providers of such investment products. There may be conflicts of interest between OCBC Bank, BOS, OSPL or other members of the OCBC Group and any of the persons or entities mentioned in this report of which OCBC Bank and its analyst(s) are not aware due to OCBC Bank's Chinese Wall arrangement. This report is intended for your sole use and information. By accepting this report, you agree that you shall not share, communicate, distribute, deliver a copy of or otherwise disclose in any way all or any part of this report or any information contained herein (such report, part thereof and information, "Relevant Materials") to any person or entity (including, without limitation, any overseas office, affiliate, parent entity, subsidiary entity or related entity) (any such person or entity, a "Relevant Entity") in breach of any law, rule, regulation, guidance or similar. In particular, you agree not to share, communicate, distribute, deliver or otherwise disclose any Relevant Materials to any Relevant Entity that is subject to the Markets in Financial Instruments Directive (2014/65/EU) ("MiFID") and the EU's Markets in Financial Instruments Regulation (600/2014) ("MiFIR") (together referred to as "MiFID II"), or any part thereof, as implemented in any jurisdiction. No member of the OCBC Group shall be liable or responsible for the compliance by you or any Relevant Entity with any law, rule, regulation, guidance or similar (including, without limitation, MiFID II, as implemented in any jurisdiction).

The information provided herein may contain projections or other forward looking statements regarding future events or future performance of countries, assets, markets or companies. Actual events or results may differ materially. Past performance figures are not necessarily indicative of future or likely performance.

Privileged / confidential information may be contained in this report. If you are not the addressee indicated in the message enclosing the report (or responsible for delivery of the message to such person), you may not copy or deliver the message and/or report to anyone. Opinions, conclusions and other information in this document that do not relate to the official business of OCBC Bank, BOS, OSPL and their respective connected and associated corporations shall be understood as neither given nor endorsed.

Co.Reg.no.: 193200032W

Additional disclosures and disclaimers applicable only to clients of Bank of Singapore Limited

This material is being made available to you through an arrangement between Bank of Singapore Limited (Co Reg. No.: 197700866R) ("BOS") and Oversea-Chinese Banking Corporation Limited ("OCBC Bank") (Co Reg. No.: 193200032W). BOS and OCBC Bank shall not be responsible or liable for any loss (whether direct, indirect or consequential) that may arise from, or in connection with, any use of or reliance on any information contained in or derived from this material, or any omission from this material, other than where such loss is caused solely by BOS' or OCBC Bank's wilful default or gross negligence.

The DIFC Branch of BOS has not conducted or produced any research contained in this material and is acting solely as a conduit in forwarding it to you.

For BOS clients in the United Kingdom:

This research has been prepared by OCBC Bank and made available to BOS. It is intended solely for informational purposes and does not constitute investment advice, a personal recommendation, or an offer or solicitation to buy or sell any financial instruments. Any payments or non-monetary benefits received or paid will be fully disclosed in accordance with applicable regulations, promptly and transparently, and will not influence the advice or services offered to you. If you would like more information about any inducements received, please contact your Relationship Manager.

Cross Border Disclaimer and Disclosures

Please refer to https://www.bankofsingapore.com/Disclaimers_and_Disclosures.html for cross-border marketing disclaimers and disclosures.